Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-de... Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. Show more
Joint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a first-in-human clinical study, continue work on...
Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and...
Expands on previously reported data showing the halting of disease progression in patients with ALS at six months and a corresponding reduction in inflammation, oxidative stress, and enhanced...
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that...
This investigator-initiated, double-blind, placebo-controlled study (funded by the Gates Foundation and Alzheimer’s Association) evaluates the safety and tolerability, biological activity, and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.97 | 14.4776119403 | 6.7 | 7.95 | 6.5301 | 58204 | 7.22378893 | CS |
4 | 0.76 | 10.998552822 | 6.91 | 7.95 | 5.76 | 47659 | 6.57794895 | CS |
12 | -0.25 | -3.15656565657 | 7.92 | 9.72 | 5.76 | 52105 | 7.58671759 | CS |
26 | 1.61 | 26.5676567657 | 6.06 | 10.6899 | 5.51 | 74425 | 8.44027549 | CS |
52 | 3.18 | 70.8240534521 | 4.49 | 10.6899 | 3.21 | 65822 | 6.963416 | CS |
156 | 2.92 | 61.4736842105 | 4.75 | 10.6899 | 3.21 | 67514 | 6.31052603 | CS |
260 | 2.92 | 61.4736842105 | 4.75 | 10.6899 | 3.21 | 67514 | 6.31052603 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.